Business
hVIVO HCM of GS-5806 in RSV for Gilead Sciences
hVIVO HCM of GS-5806 in RSV for Gilead Sciences.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 6798P Retroscreen Virology Group PLC 21 August 2014 \n \n\nFor immediate release 07.00: 21 August 2014\n \nRETROSCREEN VIROLOGY GROUP PLC\n(\"Retroscreen\" or the \"Company\")\n \nRETROSCREEN Announces results from hVIVO viral challenge study on respiratory syncytial virus\n \nRetroscreen Virology Group plc (AIM: RVG), which is pioneering its hVIVO platform of human models of disease, announces the publication of a research paper in The New England Journal of Medicine (\"NEJM\") of an important human viral challenge study of GS-5806, a small molecule antiviral, in Respiratory Syncytial Virus (\"RSV\") infection that was conducted by Retroscreen on behalf of Gilead Sciences, Inc. This paper is considered to be another major endorsement of the clinical utility of the Company's hVIVO platform in rapidly establishing proof of concept and dose selection for investigational new drugs early on in their development lifecycle. \n \nThe scientific paper titled \"Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study\" was published today in NEJM. The paper was authored by John DeVincenzo, a Professor at University of Tennessee Health Science Centre, along with co-authors including Dr Rob Lambkin-Williams from Retroscreen. It describes a double-blind, placebo-controlled human viral challenge study which was designed to establish proof of concept for GS-5806 treatment in 140 healthy adult subjects experimentally infected with RSV. RSV is a common cause of infant hospitalisations and is increasingly recognised as a cause of considerable morbidity and mortality. No accepted antiviral treatment exists. The study was conducted by Retroscreen at its purpose built, state-of-the-art clinical quarantine unit in London over a 10 month period starting in late 2012. The paper concluded that \"Treatment with GS-5806 reduced the viral load and the severity of clinical disease in a challenge study of healthy adults\". \n \nKym Denny, Chief Executive Officer, commented, \"Retroscreen is pioneering the use of its hVIVO platform of human models of disease in biomarker discovery and the clinical research of new therapies. We are delighted that this important study demonstrated proof of concept for Gilead's GS-5806 antiviral product for RSV infection in only 10 months.\"\n \nMore deta...